Best Practices in Immunotherapy – June/July 2017 Vol 8

← Back to Issue

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Combination Immunotherapy Helps Heavily Pretreated Melanoma Patients

A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.

According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, administration of nivolumab plus ipilimumab produced promising results in patients with advanced melanoma previously treated with checkpoint blockade inhibitors. The overall response rate was 21%, and more than one-quarter of patients are still without treatment failure.

In addition, said Claire Friedman, MD, the combination therapy was well tolerated by patients. Only 16% of patients experienced grade 3 immune-related adverse events, compared with 50% of patients in the frontline setting.

“These results show that combination therapy can really help patients who are heavily pretreated,” said Dr Friedman, a physician-scientist at the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center. “The patient with the longest partial response had 7 prior lines of treatment. These are patients who you would not really expect to respond.”

As Dr Friedman reported, in treatment-naive patients with advanced melanoma, the combination of nivolu­mab plus ipilimumab is associated with an impressive 52% to 58% overall response rate, but toxicity can be an issue; according to recent data, there is a 53% incidence of high-grade immune-related adverse events.

Despite this success in treatment-naive patients, the efficacy and tolerability of the combination therapy in patients previously treated with checkpoint blockade inhibitors remains unknown.

Study Design

For this phase 1 study, 19 patients, previously treated with ipilimumab or anti–PD-1 as single agents, were treated with nivolumab plus ipilimumab from December 2015 to September 2016 at Memorial Sloan Kettering Cancer Center.

Ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) were administered every 3 weeks for 4 doses, with the option to continue anti–PD-1 maintenance.

The primary end points were investigator-assessed overall response rate using RECIST v1.1, time to treatment failure, and overall survival. Dr Friedman and colleagues also collected and graded immune-related adverse events per CTCAE v4.0 and recorded the immunosuppressive drugs used to treat these events.

Nivolumab plus Ipilimumab Well Tolerated

As Dr Friedman reported, 16 patients (84%) had stage M1c disease, 2 patients (11%) had stage M1b, and 1 patient (5%) had stage IIIc. In addition, 63% of patients had cutaneous melanoma, 27% had an elevated lactate dehydrogenase level, and 26% and 21% had brain and liver metastases, respectively. The median number of prior systemic treatments was 2, with 7 being the highest.

The overall response rate was 21%—3 partial responses (16%) and 1 complete response (5%). In addition, said Dr Friedman, 5 patients (26%) treated with the combination are still without treatment failure at the time of the reporting.

“After treatment with the combination, many patients are on PD-1 maintenance therapy, and some continued on monotherapy,” Dr Friedman added.

Most remarkable about the results, however, was how well-tolerated the treatment was in this vulnerable population. Nearly half of patients (47%) received 4 cycles of nivolumab plus ipilimumab, while 5 patients (26%) stopped early for disease progression, and 4 patients (21%) stopped for toxicity.

Although 12 patients (63%) experienced an immune-related adverse event, only 3 patients (16%) had a grade 3 immune-related adverse event (rash, elevated ALT, and diarrhea). The most common grade 1/2 immune-related adverse events were diarrhea (11%), elevated ALT/AST (16%), thyroiditis/hypophysitis (21%), rash (26%), and pneumonitis (5%).

According to Dr Friedman, 6 patients (32%) required at least 1 course of steroids, and 2 patients (11%) required infliximab for steroid-refractory diarrhea.

“When compared to a 53% incidence of high-grade immune-related adverse events in treatment-naive patients, these are impressive results and suggest that combination therapy is very well tolerated,” said Dr Friedman, who hypothesized that these more advanced patients could have a less reactive immune system.

According to Dr Friedman, the investigators hope to determine whether there is a benefit to continuing PD-1 blockade with ipilimumab in combination for PD-1 refractory disease. The combination therapy is currently being evaluated in a prospective, multicenter, randomized phase 2 trial.

Related Articles
2017 ASCO-SITC Clinical Immuno-Oncology Symposium - July 19, 2017

Oncolytic Virotherapy: A New Cornerstone for Immuno-Oncology

When administered by intratumoral injection, oncolytic viruses have been shown to enhance the body’s immune response and be effective in combination with checkpoint antibodies. According to data presented at the [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium - July 19, 2017

Vaccine Shows Strong T-Cell Response in Advanced Cervical Cancer

When combined with chemotherapy, a vaccine against the human papillomavirus type 16 (HPV16) elicited strong T-cell responsiveness and improved clinical outcomes in patients with advanced cervical cancer. According to results [ Read More ]